



(51) International Patent Classification:

C07D 241/04 (2006.01) A61P 35/00 (2006.01)

A61K 31/4965 (2006.01) A61P 17/00 (2006.01)

(21) International Application Number:

PCT/US2014/027591

(22) International Filing Date:

14 March 2014 (14.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/801,112 15 March 2013 (15.03.2013) US

(71) Applicant: VM PHARMA LLC [US/US]; 45535 Northport Loop East, Fremont, California 94538 (US).

(72) Inventors: WU, Jay Jie-Qiang; c/o VM PHARMA LLC, 45535 Northport Loop East, Fremont, California 94538 (US). WANG, Ling; c/o VM PHARMA LLC, 45535 Northport Loop East, Fremont, California 94538 (US).

(74) Agents: TUSCAN, Michael, S. et al.; Cooley LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CRYSTALLINE FORMS OF TYROSINE KINASE INHIBITORS AND THEIR SALTS

Neuropathic Pain (CCI) Model in Rats (Day 14), N = 5-7/group
[F(3,38)=3.38, p=0.028, 2-way ANOVA] **p<0.01 and ***p<0.001 vs. vehicle




Figure 2.

(57) Abstract: The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.